E Fund Management’s Mirati Therapeutics, Inc. Common Stock MRTX Stock Holding History

E Fund Management’s Portfolio MRTX Stock Details MRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-8,503	Closed	-$500K	–	387
2023 Q4	$500K	Sell	8,503 -4,320	-34%	-$243K	0.03%	168
2023 Q3	$559K	Buy	12,823 +1,063	+9%	+$38K	0.04%	114
2023 Q2	$425K	Buy	11,760 +1,913	+19%	+$78.8K	0.03%	151
2023 Q1	$366K	Sell	9,847 -208	-2%	-$9.36K	0.03%	199
2022 Q4	$456K	Buy	10,055 +4,435	+79%	+$287K	0.04%	150
2022 Q3	$393K	Sell	5,620 -1,793	-24%	-$133K	0.04%	188
2022 Q2	$498K	Buy	7,413 +4,092	+123%	+$260K	0.05%	142
2022 Q1	$273K	Buy	+3,321	New	+$340K	0.01%	231

Other funds holding MRTX

Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

E Fund Management's MRTX Position: Q1 2024 in Review

E Fund Management sold out of Mirati Therapeutics, Inc. Common Stock (MRTX) in Q1 2024, closing a stake of 8,503 shares — an estimated $500K sold.

E Fund Management first reported a position in MRTX in Q1 2022 and held it in 8 quarters. The position peaked at $559K in Q3 2023. 2 funds tracked by Wall St. Rank hold MRTX as of Q1 2024.

E Fund Management reported no remaining Mirati Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
E Fund Management sold 8,503 Mirati Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $500K.
E Fund Management first reported a position in Mirati Therapeutics, Inc. Common Stock in Q1 2022 and held it in 8 quarters.
E Fund Management's Mirati Therapeutics, Inc. Common Stock position peaked at $559K in Q3 2023.
2 funds tracked by Wall St. Rank held Mirati Therapeutics, Inc. Common Stock as of Q1 2024.

Based on E Fund Management's 13F filing for Q1 2024, filed 13 May 2024.